All In Biotech

Drug Trial Radar · NCT05732402

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3)

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

72

Actual

Start

Mar 15, 2023

Primary completion

Mar 2, 2028

Study completion Mar 2, 2028

Sponsor

Lead sponsor
Alpine Immune Sciences, Inc.Industry
Sponsor type
Industry
First posted
Feb 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis - LN), or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period, participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month treatment extension period and an optional 52-week treatment extension period. Participants with IgAN and pMN may also receive povetacicept for an additional 52 weeks, if eligible.

Conditions

  • Lupus Nephritis
  • Immunoglobulin A Nephropathy
  • Membranous Nephropathy
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions

  • PovetaciceptDrug

    Administered by subcutaneous injection every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Study Day 1 Through 24 Weeks After Last Dose Of Study Drug
  2. Part B: Safety as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Study Day 1 Through 12 Weeks After Last Dose Of Study Drug

Locations

30 sites in 4 countries. Site status is shown where the registry gives one.

  • Investigational Site (523)

    Phoenix, Arizona

  • Investigational Site (501)

    Phoenix, Arizona

  • Investigational Site (524)

    Tucson, Arizona

  • Investigational Site (506)

    Valencia, California

  • Investigational Site (513)

    Arvada, Colorado

  • Investigational Site (512)

    Orlando, Florida

  • Investigational Site (525)

    Tamarac, Florida

  • Investigational Site (502)

    Lawrenceville, Georgia

  • The Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Investigational Site (503)

    Boston, Massachusetts

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri

  • Investigational Site (509)

    Newark, New Jersey

  • Investigational Site (511)

    Albany, New York

  • Investigational Site (508)

    Brooklyn, New York

  • Investigational Site (518)

    Bethlehem, Pennsylvania

  • Investigational Site (118)

    Colleyville, Texas

  • Investigational Site (516)

    Houston, Texas

  • Investigational Site (526)

    Irving, Texas

  • Investigational Site (519)

    Concord, New South Wales, Australia

  • Investigational Site (515)

    Saint Albans, Victoria, Australia

  • Investigational Site (102)

    Nedlands, Western Australia, Australia

  • Investigational Site (191)

    Caguas, Puerto Rico

  • Investigational Site (507)

    Cheonan, Chungcheongnam-do, South Korea

  • Investigational Site (505)

    Anyang-si, Gyeonggi-do, South Korea

  • Investigational Site (504)

    Goyang-si, Gyeonggi-do, South Korea

  • Investigational Site (510)

    Guri-si, Gyeonggi-do, South Korea

  • Investigational Site (125)

    Seoul, Gyeonggi-do, South Korea

  • Investigational Site (520)

    Seoul, Gyeonggi-do, South Korea

  • Investigational Site (521)

    Seoul, Gyeonggi-do, South Korea

  • Investigational Site (116)

    Suwon, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.